Upfront surgery or definitive radiotherapy for p16+ oropharyngeal cancer. A GETTEC multicentric study

Dorian Culié; Renaud Schiappa; Anouchka Modesto; Julien Viotti; Emmanuel Chamorey; Olivier Dassonville; Gilles Poissonnet; Alain Bizeau; Sebastien Vergez; Agnes Dupret-Bories; Nicolas Fakhry; Laure Santini; Benjamin Lallemant; Guillaume Chambon; Anne Sudaka; Frederic Peyrade; Esma Saada-Bouzid; Karen Benezery; Florence Jourdan-Soulier; Françoise Chapel; Anne Sophie Ramay; Pascal Roger; Thibault Galissier; Valérie Coste; Aicha Ben Lakdar; Joanne Guerlain; Haitham Mirghani; Phillipe Gorphe; Bruno Guelfucci; Renaud Garrel; Stephane Temam; Alexandre Bozec

doi:10.1016/j.ejso.2020.12.011

Upfront surgery or definitive radiotherapy for p16+ oropharyngeal cancer. A GETTEC multicentric study

Dorian Culié, Renaud Schiappa, Anouchka Modesto, Julien Viotti, Emmanuel Chamorey, Olivier Dassonville, Gilles Poissonnet, Alain Bizeau, Sebastien Vergez, Agnes Dupret-Bories, Nicolas Fakhry, Laure Santini, Benjamin Lallemant, Guillaume Chambon, Anne Sudaka, Frederic Peyrade, Esma Saada-Bouzid, Karen Benezery, Florence Jourdan-Soulier, Françoise ChapelAnne Sophie Ramay, Pascal Roger, Thibault Galissier, Valérie Coste, Aicha Ben Lakdar, Joanne Guerlain, Haitham Mirghani, Phillipe Gorphe, Bruno Guelfucci, Renaud Garrel, Stephane Temam, Alexandre Bozec

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

8 Citations (Scopus)

Résumé

Background: The aim of this study was to assess the impact of the initial therapeutic strategy on oncologic outcomes in patients with HPV-positive OPSCC. Methods: All p16-positive OPSCCs treated from 2009 to 2014 in 7 centers were retrospectively included and classified according to the therapeutic strategy: surgical strategy (surgery ± adjuvant radiotherapy and chemotherapy) vs. non-surgical strategy (definitive radiotherapy ± chemotherapy). Univariate, multivariate propensity score matching analyses were performed to compare overall (OS), disease-specific (DSS) and recurrence-free survival (RFS). Results: 382 patients were included (surgical group: 144; non-surgical group: 238). Five-year OS, DSS and RFS were 89.2, 96.8 and 83.9% in the surgical group and 84.2, 87.1 and 70.4% in the non-surgical group, respectively. These differences were statistically significant for DSS and RFS after multivariate analysis, but only for RFS after propensity score matching analysis. Conclusion: In p16+ OPSCC patients, upfront surgery results in higher RFS than definitive radiotherapy ± chemotherapy but does not impact OS.

langue originale	Anglais
Pages (de - à)	1389-1397
Nombre de pages	9
journal	European Journal of Surgical Oncology
Volume	47
Numéro de publication	6
Les DOIs	https://doi.org/10.1016/j.ejso.2020.12.011
état	Publié - 1 juin 2021

Accès au document

10.1016/j.ejso.2020.12.011

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Culié, D., Schiappa, R., Modesto, A., Viotti, J., Chamorey, E., Dassonville, O., Poissonnet, G., Bizeau, A., Vergez, S., Dupret-Bories, A., Fakhry, N., Santini, L., Lallemant, B., Chambon, G., Sudaka, A., Peyrade, F., Saada-Bouzid, E., Benezery, K., Jourdan-Soulier, F., ... Bozec, A. (2021). Upfront surgery or definitive radiotherapy for p16+ oropharyngeal cancer. A GETTEC multicentric study. European Journal of Surgical Oncology, 47(6), 1389-1397. https://doi.org/10.1016/j.ejso.2020.12.011

@article{a5c0b54679b34b6caae7c6290f8d7e5c,

title = "Upfront surgery or definitive radiotherapy for p16+ oropharyngeal cancer. A GETTEC multicentric study",

abstract = "Background: The aim of this study was to assess the impact of the initial therapeutic strategy on oncologic outcomes in patients with HPV-positive OPSCC. Methods: All p16-positive OPSCCs treated from 2009 to 2014 in 7 centers were retrospectively included and classified according to the therapeutic strategy: surgical strategy (surgery ± adjuvant radiotherapy and chemotherapy) vs. non-surgical strategy (definitive radiotherapy ± chemotherapy). Univariate, multivariate propensity score matching analyses were performed to compare overall (OS), disease-specific (DSS) and recurrence-free survival (RFS). Results: 382 patients were included (surgical group: 144; non-surgical group: 238). Five-year OS, DSS and RFS were 89.2, 96.8 and 83.9% in the surgical group and 84.2, 87.1 and 70.4% in the non-surgical group, respectively. These differences were statistically significant for DSS and RFS after multivariate analysis, but only for RFS after propensity score matching analysis. Conclusion: In p16+ OPSCC patients, upfront surgery results in higher RFS than definitive radiotherapy ± chemotherapy but does not impact OS.",

keywords = "Cancer, Human papilloma virus, Oropharynx, Radiotherapy, Surgery, Survival",

author = "Dorian Culi{\'e} and Renaud Schiappa and Anouchka Modesto and Julien Viotti and Emmanuel Chamorey and Olivier Dassonville and Gilles Poissonnet and Alain Bizeau and Sebastien Vergez and Agnes Dupret-Bories and Nicolas Fakhry and Laure Santini and Benjamin Lallemant and Guillaume Chambon and Anne Sudaka and Frederic Peyrade and Esma Saada-Bouzid and Karen Benezery and Florence Jourdan-Soulier and Fran{\c c}oise Chapel and Ramay, {Anne Sophie} and Pascal Roger and Thibault Galissier and Val{\'e}rie Coste and {Ben Lakdar}, Aicha and Joanne Guerlain and Haitham Mirghani and Phillipe Gorphe and Bruno Guelfucci and Renaud Garrel and Stephane Temam and Alexandre Bozec",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology",

year = "2021",

month = jun,

day = "1",

doi = "10.1016/j.ejso.2020.12.011",

language = "English",

volume = "47",

pages = "1389--1397",

journal = "European Journal of Surgical Oncology",

issn = "0748-7983",

number = "6",

}

Culié, D, Schiappa, R, Modesto, A, Viotti, J, Chamorey, E, Dassonville, O, Poissonnet, G, Bizeau, A, Vergez, S, Dupret-Bories, A, Fakhry, N, Santini, L, Lallemant, B, Chambon, G, Sudaka, A, Peyrade, F, Saada-Bouzid, E, Benezery, K, Jourdan-Soulier, F, Chapel, F, Ramay, AS, Roger, P, Galissier, T, Coste, V, Ben Lakdar, A, Guerlain, J, Mirghani, H, Gorphe, P, Guelfucci, B, Garrel, R, Temam, S & Bozec, A 2021, 'Upfront surgery or definitive radiotherapy for p16+ oropharyngeal cancer. A GETTEC multicentric study', European Journal of Surgical Oncology, VOL. 47, Numéro 6, p. 1389-1397. https://doi.org/10.1016/j.ejso.2020.12.011

TY - JOUR

T1 - Upfront surgery or definitive radiotherapy for p16+ oropharyngeal cancer. A GETTEC multicentric study

AU - Culié, Dorian

AU - Schiappa, Renaud

AU - Modesto, Anouchka

AU - Viotti, Julien

AU - Chamorey, Emmanuel

AU - Dassonville, Olivier

AU - Poissonnet, Gilles

AU - Bizeau, Alain

AU - Vergez, Sebastien

AU - Dupret-Bories, Agnes

AU - Fakhry, Nicolas

AU - Santini, Laure

AU - Lallemant, Benjamin

AU - Chambon, Guillaume

AU - Sudaka, Anne

AU - Peyrade, Frederic

AU - Saada-Bouzid, Esma

AU - Benezery, Karen

AU - Jourdan-Soulier, Florence

AU - Chapel, Françoise

AU - Ramay, Anne Sophie

AU - Roger, Pascal

AU - Galissier, Thibault

AU - Coste, Valérie

AU - Ben Lakdar, Aicha

AU - Guerlain, Joanne

AU - Mirghani, Haitham

AU - Gorphe, Phillipe

AU - Guelfucci, Bruno

AU - Garrel, Renaud

AU - Temam, Stephane

AU - Bozec, Alexandre

PY - 2021/6/1

Y1 - 2021/6/1

N2 - Background: The aim of this study was to assess the impact of the initial therapeutic strategy on oncologic outcomes in patients with HPV-positive OPSCC. Methods: All p16-positive OPSCCs treated from 2009 to 2014 in 7 centers were retrospectively included and classified according to the therapeutic strategy: surgical strategy (surgery ± adjuvant radiotherapy and chemotherapy) vs. non-surgical strategy (definitive radiotherapy ± chemotherapy). Univariate, multivariate propensity score matching analyses were performed to compare overall (OS), disease-specific (DSS) and recurrence-free survival (RFS). Results: 382 patients were included (surgical group: 144; non-surgical group: 238). Five-year OS, DSS and RFS were 89.2, 96.8 and 83.9% in the surgical group and 84.2, 87.1 and 70.4% in the non-surgical group, respectively. These differences were statistically significant for DSS and RFS after multivariate analysis, but only for RFS after propensity score matching analysis. Conclusion: In p16+ OPSCC patients, upfront surgery results in higher RFS than definitive radiotherapy ± chemotherapy but does not impact OS.

AB - Background: The aim of this study was to assess the impact of the initial therapeutic strategy on oncologic outcomes in patients with HPV-positive OPSCC. Methods: All p16-positive OPSCCs treated from 2009 to 2014 in 7 centers were retrospectively included and classified according to the therapeutic strategy: surgical strategy (surgery ± adjuvant radiotherapy and chemotherapy) vs. non-surgical strategy (definitive radiotherapy ± chemotherapy). Univariate, multivariate propensity score matching analyses were performed to compare overall (OS), disease-specific (DSS) and recurrence-free survival (RFS). Results: 382 patients were included (surgical group: 144; non-surgical group: 238). Five-year OS, DSS and RFS were 89.2, 96.8 and 83.9% in the surgical group and 84.2, 87.1 and 70.4% in the non-surgical group, respectively. These differences were statistically significant for DSS and RFS after multivariate analysis, but only for RFS after propensity score matching analysis. Conclusion: In p16+ OPSCC patients, upfront surgery results in higher RFS than definitive radiotherapy ± chemotherapy but does not impact OS.

KW - Cancer

KW - Human papilloma virus

KW - Oropharynx

KW - Radiotherapy

KW - Surgery

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85098668143&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2020.12.011

DO - 10.1016/j.ejso.2020.12.011

M3 - Article

C2 - 33390333

AN - SCOPUS:85098668143

SN - 0748-7983

VL - 47

SP - 1389

EP - 1397

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

IS - 6

ER -